Search Results for:
-
CBO: Health Care Costs Could Lead to Empty Glass
A 2011 study, conducted by researchers at Harvard Medical School and funded by the Pharmaceutical Research and Manufacturers of America, found that in addition to direct savings on prescription drugs, Part D significantly reduced the number of avoidable hospitalizations, leading to a $13.7 billion savings in 2007 alone. (See BioWorld Today, July 25, 2011, and Oct. 10, 2011.) In another congressional effort to lower drug prices, Klobuchar teamed up with SenBy Mari Serebrov | BioWorld Today | Thursday, February 7, 2013 -
Ritter Feeds Good Bugs To Fight Lactose Intolerance
Despite the unmet need in a fairly large market, no prescription drugs have been developed to treat lactose intolerance...Ritter Pharma's solution is a prescription drug called RP-G28, an oligosaccharide designed to produce colonic adaption, a process that changes the microbiota in the large intestineBy Brian Orelli | BioWorld Insight | Monday, January 14, 2013 -
FDA Submissions, Approvals & Other Actions: December 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, January 14, 2013 -
Washington Roundup
The draft guidance fulfilled mandates under the Food and Drug Administration Safety and Innovation Act and the Office of National Drug Control Policy's Prescription Drug Abuse Prevention PlanBioWorld Today | Thursday, January 10, 2013 -
BioWorld's Top 10 Countdown of 2012's Most Impactful Stories
Besides setting prescription drug and medical device fees for the next five years, the legislation created new user fees for generic and biosimilar drugsBy BioWorld Staff | BioWorld International | Wednesday, January 2, 2013 -
Other News To Note
The Prescription Drug User Fee Act date is SeptBioWorld Today | Friday, December 28, 2012 -
BioWorld's Top 10 Countdown of 2012's Most Impactful Stories
Besides setting prescription drug and medical device fees for the next five years, the legislation created new user fees for generic and biosimilar drugsBy BioWorld Staff | BioWorld Today | Thursday, December 27, 2012 -
Taking ACTTION to Improve Development of Analgesics
Yet discovering new pain therapies has been a challenge for the industry despite the obvious huge rewards waiting for those companies that could deliver drugs as effective as opioids minus the qualities that causes prescription drug abuse and safety issues. (See BioWorld Insight, Aug. 13, 2012.) To help address this situation, the public-private partnership Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) was formedBy Peter Winter | BioWorld Insight | Wednesday, December 26, 2012 -
FDA Submissions, Approvals & Other Actions: November 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, December 10, 2012 -
FDA Keeps Up the Pace on New Medicine Approvals
The report noted that 34 out of the 35 drugs (97 percent) met the target dates agreed to under the Prescription Drug User Fee Act (PDUFA), surpassing its goal of reviewing and acting on 90 percent of new molecular entities (NMEs) by their target datesBy Peter Winter | BioWorld Today | Friday, December 7, 2012 -
CBO: New Findings on Prescriptions, Medicare Spend
Previously, CBO had found insufficient evidence of an offsetting effect of prescription drug use on spending for medical servicesBy Staff Reports | BioWorld Today | Monday, December 3, 2012 -
FDA Issues Final Guidance on Drug Manufacturing Processes
Under section XII of the Prescription Drug User Fee Act V performance goals, the FDA also agreed to create a plan for distinct therapeutic area data standards and to prioritize and develop the data standards in collaboration with industry, the Clinical Data Interchange Standards Consortium, the Critical Path Institute, Health Level 7's Clinical Interoperability Council and other organizationsBy Staff Reports | BioWorld Today | Tuesday, November 20, 2012 -
FDA Submissions, Approvals & Other Actions: October 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, November 19, 2012 -
Week in Washington
The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion, issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the productBioWorld Insight | Monday, November 12, 2012 -
Washington Roundup
The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the productBioWorld Today | Tuesday, November 6, 2012 -
Washington Roundup
They asked the DEA to establish clear regulatory guidance to ensure that the laws governing prescription drug supplies are applied consistently without threatening the well-being of patientsBioWorld Today | Tuesday, October 16, 2012 -
FDA Submissions, Approvals & Other Actions: Sept. 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, October 15, 2012 -
Week in Washington
President Obama has signed into law the SAFE DOSES Act, which will increase penalties for prescription drug crimes such as robbing pharmacies and medical product cargoBioWorld Insight | Monday, October 15, 2012 -
Other News To Note
In separate news, Genentech received a letter from the FDA's Office of Prescription Drug Promotion stating that the visual aids included in advertisements for cancer drug Tarceva (erlotinib) are misleading because they contain "misleading efficacy claims, minimize the risks and overstate the efficacy of TarcevaBioWorld Today | Monday, October 15, 2012 -
Safe Drugs, User Fees, High Tech Finish Busy Session
President Obama has signed into law the SAFE DOSES Act, a law that will increase penalties for prescription drug crimes like robbing pharmacies and medical product cargo...As well, the bill's sponsors hope to stem the rising tide of prescription drug abuseBy Catherine Shaffer | BioWorld Today | Tuesday, October 9, 2012
Category
Current Filters
- xPrescription Drug
Related Keywords
Categories
- x BioWorld Today (780)
- x BioWorld Insight (141)
- x Bio Perspectives (45)
- x BioWorld International (38)
- x State of the Industry Report (24)
- x Top 25 Drug Report (13)
- x BioWorld Snapshots (4)
- x RNAi Report (1)
- x BioWorld Genomics Review (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.